Foster James C sells $10.1M of CRLFoster James C 内部减持 查尔斯河 (CRL) $10.1M
Insider Sale Transaction
On August 25, 2026, FOSTER JAMES C, a director of Charles River Laboratories International, Inc. (ticker: CRL), sold 33,561 common shares on the open market at a price of $300.00 per share, for a total transaction value of $10,068,300. The corresponding Form 4 insider trading filing was submitted to the U.S. Securities and Exchange Commission (SEC) on August 27, 2026. This sale represents 0.071% of CRL’s current $14.3 billion market capitalization, making it a moderate-sized position adjustment for a company director, providing market participants with an independent ownership signal.
Transaction Signal and Contextual Comparison
This transaction represents an actual open-market sale by a company director, distinct from the small gift or exempt trades filed by other insiders in recent weeks. Comparing to recent CRL Form 4 filings: on August 13, 2026, CEO Birgit Girshick sold 6,500 shares for $1,819,350; on August 20, 2026, Executive Vice President Shannon M. Parisotto sold 2,039 shares for $599,711, and Director Nancy C. Andrews sold 573 shares for $163,443. FOSTER JAMES C’s recent sale is significantly larger than the August 20 trades, and nearly 5.5 times the size of the CEO’s August 13 sale.
Cross-Validated Market Signal
Per public institutional holding data, as of December 31, 2025, CRL had 589 institutional holders, an increase of 21 from the prior quarter, with total institutional holdings of $10.5 billion representing 107.4% of the company’s outstanding float. Of these holders, 113 established new positions, 288 increased their stakes, 208 reduced their positions, and 89 fully exited their holdings. This insider sale does not directly conflict with the recent overall institutional holding trend, and stands as an independent ownership signal.
Transaction Limitations and Follow-Up Markers
This Form 4 disclosure only covers the volume, price, and filing date of the sale, and does not provide insight into the transaction’s motivation (such as personal cash flow needs, valuation judgments, etc.), nor does it confirm whether the trade was executed under a pre-arranged 10b5-1 trading plan. It also cannot directly predict future company performance or stock price movement. Key follow-up items include additional insider trading filings for CRL, the quarterly earnings report scheduled for November 4, 2026, and the next institutional holding update.
本次董事减持交易
2026年8月25日，Charles River Laboratories International, Inc.（股票代码CRL）董事FOSTER JAMES C以每股300.00美元的价格在公开市场出售33,561股公司普通股，交易总价值为10,068,300美元。相关Form 4内幕交易申报文件于2026年8月27日提交至美国证券交易委员会（SEC）。该减持规模占CRL当前143亿美元市值的0.071%，属于董事层级的中等规模持仓调整，为市场参与者提供了独立的内部所有权信号。
交易信号与背景对比
作为公司董事，FOSTER JAMES C的本次交易属于实际公开市场减持，而非此前其他内部人士的小额赠予或豁免交易。对比近期CRL内部人士的Form 4申报记录：2026年8月13日，首席执行官Birgit Girshick出售6,500股，价值1,819,350美元；2026年8月20日，执行副总裁Shannon M. Parisotto出售2,039股，价值599,711美元，董事Nancy C. Andrews出售573股，价值163,443美元。本次FOSTER JAMES C的减持规模显著高于8月20日两位内部人士的减持金额，接近首席执行官8月13日减持规模的5.5倍。
交叉验证信号
结合公开机构持仓数据，截至2025年12月31日，CRL共有589家机构持有人，较上一季度增加21家，总持仓规模达105亿美元，占公司流通股的107.4%，其中113家机构新建仓，288家加仓，208家减仓，89家完全清仓。本次内部人士减持未与近期整体机构持仓趋势形成直接背离，属于独立的内部所有权信号。
交易局限与后续关注
本次Form 4披露的交易数据仅涵盖减持的数量、价格和申报时间，无法推断交易动机（如个人现金流需求、对公司估值的判断等），也未确认是否基于10b5-1预先安排交易计划，同时无法直接预测公司未来股价或业务表现。后续关注重点包括CRL后续提交的其他内幕交易申报文件、2026年11月4日即将发布的季度财报，以及下一期机构持仓更新数据。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。